IMAB I-MAB ADS (N Shares)

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab to Present at Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig.

I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.

Conference details are as follows:

Jefferies Global Healthcare Conference

Format: Fireside Chat and one-on-one meetings

Date: Thursday, June 5, 2025

Time: 3:45 PM ET

Webcast Link: Register

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit and follow us on and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors









EN
20/05/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge to Host Business Update Call to Review Phase 2a Data for VI...

NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO  Visara, a NovaBridge Majority-Owned Subsidiary, Holds Global Rights to VIS-101 Outside of Greater China and Certain Asian Territories ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biote...

4h / 28m 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare C...

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that NovaBridge’s management team will participate in the upcoming Leerink Partners 2026 Global Healthcare Conference being held on March 8-11, 2026. Conference details are as follows: Leerink Partners Global Healthcare ConferenceFormat: Fireside Chat Date: Wednesday, March 11, 2026...

March 2, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD,...

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge su...

February 19, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of ...

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic gastric cancerMajor milestone builds on positive Phase 1b combination data demonstrating that givastomig produced, best-in-class potential efficacy in 1L HER2-negative, metastatic gastric cancer patients in combination ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu W...

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to $5,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company’s ADSs in open market transactions. T...

January 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch